Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus

Table 1 Baseline characteristics of the study patients n (%)

Recipient characteristics	n
Median age (yr)	182	52 ± 8.2
Male gender	182	145 (80)
Ethnicity	182
Caucasian		91 (50)
Black		18 (10)
Hispanic		52 (29)
Asian		14 (8)
Arabic		6 (3)
Others		1 (1)
IL28B	122
CC		40 (33)
CT		51 (42)
TT		31 (25)
HCC (pre-LT)	182	75 (41)
Diabetes mellitus	182	71 (39)
CMV positivity	181	126 (70)
Duration from LT to anti-viral therapy (mo)	182	20.5 ± 43.5
Median peak PEG dose (mcg/wk)	181	180 ± 31.6
Median peak RBV daily dose (mg)	181	800 ± 294
Median treatment duration (wk)	182	48 ± 21.5
HCV genotype	182
1		141 (77)
1a		80/141 (57)
1b		51/141 (36)
Subtype not available		10/141 (7)
2		15 (8)
3		14 (8)
4		12 (7)
Median baseline lab values
ALT (IU)	181	84 ± 128.3
AST (IU)	181	80 ± 112.5
ALP (IU)	180	131 ± 144.3
Total bilirubin (mg)	181	0.9 ± 3.1
HCV RNA (IU/mL)	181	3870000 ± 23602918
Hemoglobin (g/dL)	180	13 ± 1.7
White cell count	180	4.3 ± 1.9
Platelets	181	123 ± 73
Creatinine	181	1.2 ± 1.3
Immunosuppression at start of LADR1	182
Tacrolimus		146 (80)1
Cyclosporine		25 (14)
Sirolimus		4 (2)
Mycophenolate mofetil		66 (36)
Prednisone		9 (5)
Donor characteristics
Male gender	175	99 (57)
Median age	177	48 ± 18
CMV positivity	178	117 (66)
Ethnicity	182
White		118 (65)
Black		26 (14)
Hispanic		12 (7)
Asian		6 (3)
American indian/alaskan native		3 (2)
Other/unknown		17 (9)
Donor IL28B	122
CC		66 (54)
CT		35 (29)
TT		21 (17)

¹Percentages add to > 1 due to combination therapy. HCC: Hepatocellular carcinoma; LT: Liver transplant; CMV: Cytomegalovirus; HCV: Hepatitis C virus; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; LADR: Low-accelerating-dose regimen.